Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMB-1018972 in refractory angina
NCT04306237Phase 2Withdrawn
- Sponsor
- Imbria Pharmaceuticals
- Start
- May 2020
- Primary completion
- Feb 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of ninerafaxstat in Angina Pectoris (AP), sponsored by Imbria Pharmaceuticals. Planned start May 2020; status: withdrawn.
02
Drugs
ninerafaxstat
03
Conditions
Angina Pectoris (AP)
Beyond the preview
Go deeper on NCT04306237.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04306237.